Press release

RESCEU: Fighting Respiratory Syncytial Virus and its economic impact

2020

Europe’s project RESCEU sheds new light on the fight against the Respiratory Syncytial Virus (RSV) and its economic impact

Read More

RECOVER enrolls first patients in its COVID-19 studies!

2020

Big achievements in the RECOVER project: on April 22nd the first patient was enrolled in the “Household transmission study” – part of the RECOVER project- aimed at investigating the spread of SARS-CoV-2 infection within households,

Read More

RECOVER: a new project approved by EU to tackle COVID-19

2020

Antwerp, Belgium – 11 March, 2020

The University of Antwerp has launched Rapid European COVID-19 Emergency Research response (RECOVER), in collaboration with 9 international partners.

Read More

PREPARE activated to Mode 3 as COVID-19 cases in Europe increases

2020

Antwerp, Belgium – 3 March 2020

The EU-funded Platform foR European Preparedness Against (Re-) emerging Epidemics (PREPARE) has decided to upgrade its response efforts to the novel Coronavirus (SARS-CoV-2) epidemic to Outbreak Research Response Mode 3,

Read More

PREPARE continues active measures as novel Coronavirus outbreak in Italy unfolds

2020

Antwerp, Belgium – 24 February 2020

Confirmed SARS-CoV-2 infected patients have been reported in Europe for several weeks now and PREPARE has been monitoring developments very closely.

Read More

PREPARE activated to Mode 2 in response to novel Coronavirus cases in Europe

2020

Antwerp, Belgium – 6 February 2020

On 30th January 2020, the Director General of the World Health Organisation (WHO) declared the outbreak of 2019-nCoV a public health emergency of international concern.

Read More

🇬🇧 University of Antwerp, bioMérieux, and Wellcome Trust to coordinate VALUE-Dx, a European Public-Private Partnership to fight antimicrobial resistance through diagnostics

2019

Antwerp (Belgium), London (UK), Marcy l’Etoile (France) – April 1, 2019

The University of Antwerp, bioMérieux and Wellcome Trust today announced the launch of VALUE-Dx, the first Innovative Medicines Initiative (IMI) project initiated by six in vitrodiagnostic companies who join forces with 20 non-industry partners to combat antimicrobial resistance (AMR) and improve patient outcomes.

Read More